Podcasts about Molecular imaging

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Life Healthcare R14bn sale of Life Molecular Imaging is the focus of this edition of Business Day Spotlight. Host Mudiwa Gavaza is joined by Peter Wharton-Hood, CEO of Life Healthcare Group. Topics of discussion include: Peter Wharton-Hood outlines the rationale for the transaction; relationship with Lantheus; capital allocation; and investment in technology. Business Day Spotlight is a MultimediaLIVE Production

Stephen Grootes speaks to Life Healthcare CEO Peter Wharton-Hood about the company's $750 million sale of Life Molecular Imaging to Lantheus Neurology UK Limited.See omnystudio.com/listener for privacy information.

Nosipho Radebe speaks to Peter Wharthon-Hood, CEO at Life HealthcareSee omnystudio.com/listener for privacy information.

Terry Pearl is a proven leader and successful strategist in development, strategic planning, fundraising campaigns, major gifts, corporate and foundation relations, and board development. Over a philanthropic career spanning two decades, she has cumulatively raised more than $175 million for nonprofits across the globe, including principal gifts as large as $50 million. As a development consultant, she has worked with a diverse group of organizations including the Society of Nuclear Medicine and Molecular Imaging, American Society for the University of Haifa, Hadassah of America, HousingPlus, the Green Beret Foundation, the Network of Jewish Human Service Agencies, T1D Exchange, the YWCA of New York City, Overlook Medical Center, and several Hackensack Meridian Health hospitals. 

GUEST: John Ronald, London (ON, Canada)Welcome back!  It has been a while but are back with a bang, having our good friend John Ronald from The Robarts Research Institute in London, Ontario as our guest. John's group combines advances in molecular and synthetic biology with a multimodal imaging perspective to build new tools for early detection and treatment of cancer, as well as non-invasive monitoring of cell, gene and genome therapies. One of John's passions is gene reporter imaging, which is also the main focus of this edition. The paper up for discussion comes from Cynthia Dunbar's lab at NIH, Bethesda which was recently published in Cell Stem Cell. We discover their approach to non-invasively follow engraftment and maturation of pluripotent stem cells in rhesus macaques with myocardial infarctions, discuss some of the technicalities of engineering autologous cells, and fall in love with the beautiful RNAScope images that are presented. We discuss what makes a good imaging reporter, why one size doesn't always fit all, and a future where not just cells, but activation states can be imaged. Along the way, John also shares advices received from the wonderful Sanjiv Sam Gambhir on how to improve the chances of getting your grants funded and that supposedly crazy ideas should not be discarded... they might even lead to high impact publications.And of course, true to our tradition, we enjoy a special cocktail. For this edition the “Angry Canadian”, obviously. For the curious listeners: a good measure of Whisky, 2 tablespoons of fine Canadian Maple syrup, a few drops of bitters and 1 teaspoon lemon juice, then top up with soda water.Selected Publication: Lin Y, Sato N, Hong S, Nakamura K, Ferrante EA, Yu ZX, Chen MY, Nakamura DS, Yang X, Clevenger RR, Hunt TJ, Taylor JL, Jeffries KR, Keeran KJ, Neidig LE, Mehta A, Schwartzbeck R, Yu SJ, Kelly C, Navarengom K, Takeda K, Adler SS, Choyke PL, Zou J, Murry CE, Boehm M, Dunbar CE. Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques. Cell Stem Cell. 2024 Jul 5;31(7):974-988.e5. doi: 10.1016/j.stem.2024.05.005. Epub 2024 Jun 5. PMID: 38843830; PMCID: PMC11227404. https://www.cell.com/cell-stem-cell/abstract/S1934-5909(24)00182-6Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu 

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.Read the Commission:https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Join us for an inspiring discussion with Dr. Akiva Mintz, a physician-scientist whose translational research focuses on developing and personalizing cancer therapies using non-invasive molecular imaging. Learn about the role of nuclear medicine in molecular based cancer therapies and the life of a physician scientist.

This podcast is brought to you by United Imaging, co-chair of the SNMMI Value Initiative Industry Alliance. Hosts Dr. Munir Ghesani, former President of SNMMI, co-Chair of the Mars Shot Research Fund, and Dr. Stephen Lokitz, a NM physician at the Center for Molecular Imaging and Therapy, or CMIT, discuss nuclear medicine procedures performed and their plans for the future."

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: https://auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

In today's episode, we delve into the world of PET scans and other imaging modalities crucial for accurate diagnosis and staging of breast cancer. We are joined by two incredible guests: Dr. Kiser, the Medical Director of Molecular Imaging for Carilion Clinic, and Pam Kohl, a patient advocate living with metastatic breast cancer.Dr. Kiser provides an in-depth explanation of PET scans, particularly focusing on FDG and FES (also known as Cerianna) PET scans. FDG-PET scans use radioactive glucose to highlight cancerous tissues, while FES-PET scans target estrogen receptors, making them highly specific for ER-positive breast cancer. Dr. Kiser emphasizes the revolutionary impact of these imaging techniques in both diagnostics and therapeutics.Pam shares her personal experience with breast cancer, highlighting the importance of advocating for oneself. Diagnosed with early-stage breast cancer in 2009, Pam experienced a recurrence in 2017, which led to a stage 4 metastatic diagnosis. Her story underscores the critical role of PET scans in detecting metastasis early and informing effective treatment plans. Pam's experience with FES-PET scans has been particularly transformative, allowing her medical team to tailor her treatment precisely to her cancer's characteristics.SURVIVINGBREASTCANCER.ORGAttend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsFollow us on InstagramSurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the Show.

Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches. Dr. Antonio Strafella discusses current practices for using molecular imaging biomarkers in research and in the clinic, the process of developing new biomarkers, as well as promising biomarkers that are in development. He also discusses limitations, implementation challenges, and the potential use of AI to enhance diagnostics in the future. Antonio is the Krembil-Rossy Chair in Molecular Imaging of Neurodegenerative Diseases and Professor in the Department of Medicine within the Division of Neurology at the Toronto Western Hospital (University Health Network, University of Toronto). He also serves as Director of Clinical Research and Translation with the Temerty Faculty of Medicine at the University Toronto, and he is a movement disorder neurologist in the Edmond J. Safra Program in Parkinson's Disease and Morton & Gloria Shulman Movement Disorders Clinic at the Toronto Western Hospital.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches. Dr. Antonio Strafella discusses current practices for using molecular imaging biomarkers in research and in the clinic, the process of developing new biomarkers, as well as promising biomarkers that are in development. He also discusses limitations, implementation challenges, and the potential use of AI to enhance diagnostics in the future. Antonio is the Krembil-Rossy Chair in Molecular Imaging of Neurodegenerative Diseases and Professor in the Department of Medicine within the Division of Neurology at the Toronto Western Hospital (University Health Network, University of Toronto). He also serves as Director of Clinical Research and Translation with the Temerty Faculty of Medicine at the University Toronto, and he is a movement disorder neurologist in the Edmond J. Safra Program in Parkinson's Disease and Morton & Gloria Shulman Movement Disorders Clinic at the Toronto Western Hospital.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it's going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it's going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Guest: Joyita Dutta The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what's on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in the Department of Biomedical Engineering, who also presented this at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Guest: Joyita Dutta The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what's on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in the Department of Biomedical Engineering, who also presented this at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Molecular imaging tests can offer comprehensive views of breast cancers, especially for locally advanced or metastatic breast cancer, and can help paint a clearer picture of the extent and characteristics of the cancer. This can then give doctors the ability to help guide treatment and evaluate response to treatment. Joining us on today's show is Dr. David Mankoff, Vice Chair of Research, Radiology and the Matthew J. Wilson Professor of Radiology at the University of Pennsylvania and Associate Director of Education and Training at Penn's Abramson Cancer Center. Dr. Mankoff is going to help us understand the complexities of breast cancer tumors, what these molecular imaging tests are looking for and who should be getting them.

What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances.MEET DR. RIHAM EL KHOULI, MD, PHDAssociate Professor of Radiology, UK College of MedicineChief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R)Director, Radiotheranostics ProgramUniversity of KentuckyDr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine.TOP TEN QUESTIONS ABOUT NET TREATMENTS:1. What is PRRT?  How does it work? 2. What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT?3. How do you determine who is eligible for PRRT?4. When is PRRT given in one's treatment journey? 5. How does PRRT differ from other treatments?6. What are the common side effects of Lutathera?a. Does Lutathera have long-lasting effects?b. Would receiving Lutathera affect one's blood counts?c. How might Lutathera affect one's liver function? When, if ever is there concern about liver failure?7. How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? a. What precautions do I need to follow?b. Can I hug my child? Can I pet my dog? c. Would receiving Lutathera cause someone to be immunocompromised? 8. How to you decide who should get PRRT?a. What is peritoneal disease and how effective is PRRT with peritoneal disease?9. How do you assess the response to PRRT? 10. What advances in PRRT are you most excited about? Visit https://www.lacnets.org/podcast/34. For more information, visit LACNETS.org.

Radiopharmaceuticals are precision nuclear medicines used for medical imaging and treatment that allow doctors to diagnose and deliver targeted therapies for diseases such as cancer. A new discussion paper from MTPConnect, ‘From Mines to Medicines. Australia's Radiopharmaceuticals Future' reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies drive significant investment and rapid expansion. South Australia is identified as the ideal location to lead the development of Australia's radiopharmaceuticals future, with end-to-end capabilities – from unique mining assets and a robust research ecosystem through to cutting-edge clinical services and specialised workforce. In this feature length episode, hosts Caroline Duell and Dana Bell, MTPConnect's Partnerships Director South Australia, speak to experts in South Australia along the supply chain - from mines to medicines including: UniSAs Professor Eva Bezak, Deputy Director of the Australian Research Council's Industrial Transformation Training Centre (ITTC) for Radiation Innovation (Time code: 10.32) on researching new radiopharmaceuticals and building a highly skilled workforce to scale up,  SAHMRI's Chady Barkil, Director, Molecular Imaging and Therapy Research Unit (MITRU) (Time code: 35.43) on manufacturing nuclear medicines and the supply chain challenges,EntX's Dr Massey de Los Reyes, Principal Scientist and Facilities Manager, on developing technology to transform mining waste into medical isotope production (at Time code: 57.36),Novartis ANZ's Matt Zeller, Country President (Time code: 1.17.03) on how the company is reimagining cancer care with its precision nuclear medicine pipeline,Artesian's Stephanie Morris, Investment Manager (Time code: 1.36.02) discusses the investment activity and interest in the growing radiopharmaceuticals market and,Department for Industry, Innovation and Science's Dr Judy Halliday, Director Innovation and Entrepreneurship (Time code: 1.48.06) outlines South Australia's strengths as a first mover to unlock the radiopharmaceutical industry opportunity. 

In this episode of Talking HealthTech recorded at Healthcare Week in Hamilton New Zealand, host Peter Birch speaks with Jane Prowse, CTO of FiveP, and Nicole Hosking, Operations Director for Radiology and Molecular Imaging and Therapy at Austin Health. They discuss the development of the Baret role-based communicator app, a solution that addresses communication challenges in Austin Health. Jane and Nicole share insights into the creation of the app, its functionality, and the impact it has had on clinical workflows.Key Takeaways:- The Baret app was developed to address complex communication challenges, such as finding the right person to communicate with 24/7 and minimising the use of multiple communication methods.- The app leverages Microsoft Teams for seamless integration, reducing the need for additional logins and authentication steps.- Baret focuses on clinical governance, incorporating measures to ensure communication quality, safety, and risk management within the hospital environment. It also provides valuable data insights for better assessment of communication quality and workload.Check out the episode and full show notes on the Talking HealthTech website.Loving the show? Leave us a review, and share it with someone who might get some value from it.Keen to take your healthtech to the next level? Become a THT+ Member for access to our online community forum, quarterly summits, and more exclusive content. For more information visit talkinghealthtech.com/thtplus

Dr. Linda Chu discusses the future of molecular imaging with Dr. Umar Mahmood, Chair of the RSNA Board of Directors.   Molecular Imaging, Oncology, and the Arc toward Our Precision Future. Mahmood. Radiology 2023; 309(2):e231930.

Some of the rarest, most complex, challenging and difficult NETs are known as pheochromocytomas and paragangliomas. This is an updated version of an episode that first aired in 2021. A special thank you to Dr. Erik Mittra Chief of Nuclear Medicine and Molecular Imaging at Oregon Health and Science University for his expert assistance with […] The post NETWise Episode 32: Pheos & Paras (updated episode) appeared first on NETRF.

We celebrate the start of 2024 with a cracking podcast to showcase the January edition of European Urology!! Co-hosts Declan Murphy and Joyce Baard highlight two key papers (details below) from this month's journal, including interviews with key authors and expert commentators. We also look at other highlights in this month's journal with guest contributor Dr Stefani Croghan (Dublin).  Even better on our YouTube channelPodcast Priority Papers1. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate CancerFeatured author - Dr Daniela Oprea-Lager (Amsterdam University Medical Centre)Discussant - Dr Roderick van den Bergh (Erasmus Medical Centre, Rotterdam)2. The Role of Multiparametric MRI and MRI–targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial Featured author - Dr Taimur Shah (Imperial College, London)Discussant - Dr Amar Kishan (University of California, Los Angeles)Full index to European Urology January 2024 

GUEST: Kevin Brindle, CambridgeIn this episode we welcome the one and only Kevin Brindle from University of Cambridge.During his long and illustrious career, Kevin pioneered hyperpolarized magnetic resonance spectroscopy as a method to map metabolic flux in cancer and other diseases, with implications for treatment response monitoring.We explore how deuterium imaging and [18F]FDG PET can be used to track the metabolic changes that occur soon after stroke and during the recovery phase. We discuss the complementary information that these two techniques provide and whether they could be used to improve clinical outcomes.Along the way, we learn how Kevin could have worked in structural biology or been a painter and decorator... and how he used to meet his wife-to-be in the cold room when he was a postdoc at Oxford.Selected Publication: In vivo imaging of cerebral glucose metabolism informs on subacute to chronic post-stroke tissue status - A pilot study combining PET and deuterium metabolic imaging. Meerwaldt AE, Straathof M, Oosterveld W, van Heijningen CL, van Leent MM, Toner YC, Munitz J, Teunissen AJ, Daemen CC, van der Toorn A, van Vliet G, van Tilborg GA, De Feyter HM, de Graaf RA, Hol EM, Mulder WJ, Dijkhuizen RM. J Cereb Blood Flow Metab. 2023 May;43(5):778-790. doi: 10.1177/0271678X221148970. Epub 2023 Jan 6.https://journals.sagepub.com/doi/10.1177/0271678X221148970 Further information on the European Society for Molecular Imaging: https://e-smi.eu/ Contact: office@e-smi.eu 

Guest host Dr. Gagandeep Choudhary summarizes the article “Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging” focusing on pathophysiology and imaging findings of some of the major neurodegenerative processes.  Multimodality Imaging of Demen-tia: Clinical Importance and Role of Integrated Anatomic and Mo-lecular Imaging. Patel et al. RadioGraphics 2020; 40:200–222.

GUEST: Mikhail Shapiro, PasadenaIn this episode we welcome our famous guest Mikhail Shapiro from Caltech. Mikhail exquisitely combines ultrasound with synthetic biology for gene regulation, imaging, and therapy - and Synthetic biology is surely the common thread in this podcast edition.We discover how an engineered receptor and an intracellular signalling domain, known as ‘synNotch' can be used to visualise cell-cell communication in vivo. And how this system can be used to identify immune-cancer cell interactions, why it provides far more information than just knowing where the immune cells reside, and the various merits of the three different reporter genes employed for visualisation across scales.We also reveal some insider information into the review process for the selected paper from the senior author John Ronald. Along the way, we speculate why the synNotch system improves NK cell kill and Tim ends up dreaming of sheep jumping over logic gates!Selected Publication: Visualizing cell–cell communication using synthetic notch activated MRI. TianDuo Wang, Yuanxin Chen, Nivin N Nystrom, Shirley Liu, Yanghao Fu, Francisco M Martinez, Timothy J Scholl, and John A Ronald. Proc Natl Acad Sci U S A. 2023 Mar 14; 120(11):e2216901120. doi: 10.1073/pnas.2216901120.https://www.pnas.org/doi/abs/10.1073/pnas.2216901120Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

This week we have a very special guest, Hilma Johnson, account executive at DISS Medical Solutions and Molecular Imaging specialist. In this episode we talk about the importance of Molecular Imaging in accurate diagnoses and his experience as a nuclear medicine technologist.

In questo audio il prezioso incontro con Ennio Tasciotti biotecnologo e Lucrezia Reichlin economista. L'intervista è in Contemporaneamente di Mariantonietta Firmani, il podcast divulgato da Artribune.com e Parallelo42.it In Contemporaneamente podcast trovate incontri tematici con autorevoli interpreti del contemporaneo tra arte e scienza, letteratura, storia, filosofia, architettura, cinema e molto altro. Per approfondire questioni auliche ma anche cogenti e futuribili. Dialoghi straniati per accedere a nuove letture e possibili consapevolezze dei meccanismi correnti: tra locale e globale, tra individuo e società, tra pensiero maschile e pensiero femminile, per costruire una visione ampia, profonda ed oggettiva della realtà. Ennio Tasciotti e Lucrezia Reichlin ci raccontano di cellule e cicli economici, passione alimentata dalla qualità delle relazioni, confronto con i giovani e nessi causali. Tra 100mila chilometri di vasi sanguigni e 300miliardi di cellule quotidianamente rigenerate, nell'arco della vita ciascuno sviluppa una decina di principi tumorali risolti dal sistema immunitario. L'economia descrive il comportamento economico degli esseri umani, ma i modelli di previsione economici non si occupano dei poveri. In America la gestione big data estratti dai cittadini è promossa dalle assicurazioni per elaborare i premi assicurativi. Mentre, in Italia la gestione dati ad opera dello stato, mira ad abbassare i costi della sanità ed efficientare il sistema, e molto altro. ASCOLTA L'INTERVISTA INTEGRALE!! GUARDA IL VIDEO!! https://youtu.be/G3O9WP_uglE BREVI NOTE BIOGRAFICHE DEGLI AUTORI Ennio Tasciotti laurea in Biologia Molecolare alla Scuola Normale Superiore di Pisa, PhD in Molecular Medicine all'International Center for Genetic Engineering & Biotechnology. Poi 2 specializzazioni: in “Molecular Imaging” al Consorzio di Biomedicina Molecolare, AREA Science Park; in “Nanomedicina” alla University of Texas Health Science Center di Houston. Attualmente Ordinario di Biotecnologie all'Università San Raffaele di Roma dove è Direttore dello Human Longevity Program dell'IRCCS.Dal 2010 ottiene oltre $50 milioni di finanziamenti: $15 milioni da Dipartimento della Difesa e Pentagono per creare soluzioni per rigenerare le ferite di guerra. Ed anche $10 milioni dal National Institute of Health (NIH) per terapie mirate per il cancro. Inoltre, $25 milioni in supporto istituzionale per nuovi programmi scientifici di ricerca traslazionale su: medicina personalizzata, medicina rigenerativa e medicina digitale. Chairman del Department of Nanomedicine (2010-2015), fondatore e direttore del Center for Biomimetic Medicine e del Center for Musculoskeletal Regeneration (2015-2020) presso Houston Methodist Hospital. È anche autore di 14 libri tecnici, oltre 300 conferenze, 185 articoli di ricerca con oltre 10.000 citazioni. Infine, detiene 12 brevetti internazionali su nanomateriali e biomateriali per uso biomedico, alcuni dei quali concessi in licenza a società private. Lucrezia Reichlin professore ordinario di economia alla London Business School, è fiduciario della Fondazione “International Financial Reporting Standards” (IFRS); membro esterno del think-tank Bruegel. È inoltre, fellow della British Academy, della Econometric Society; honorary international fellow di “American Economic Association”; distinguished fellow del Center of European Policy Research. Infine, ha ricevuto dal Presidente della Repubblica, l'onorificenza “Grande Ufficiale della Stella d'Italia”.Già direttore generale alla ricerca della Banca Centrale Europea, è membro di alcuni consigli di amministrazione di società commerciali e istituti di ricerca internazionali. Tra i quali: Messaggerie Italiane Group (Milano), Eurobank Ergasias (Atene), Ageas Insurance Group (Bruxelles), Unicredit Group. In più è consulente di governi e banche centrali su argomenti legati alle politiche macroeconomiche e finanziarie. È anche co-fondatrice della società di previsioni “now-casting economics ltd”; co-fondatrice e presidente della Fondazione Ortigia, no-profit che promuove attività di supporto all'istruzione nell'Italia meridionale. Inoltre è Editorialista per: Corriere della Sera e Project Syndacate; pubblica numerosi articoli in riviste internazionali come: Review of Economic Studies e Journal of Econometrics. Nel 2016 il premio “Birgit Grodal Award” della European Economic Association per l'originale metodo di analisi delle serie temporali per la previsione dei cicli economici.

GUEST: Jason Lewis, New YorkIn this episode we discuss and learn about new PSMA-binding ligands with 161Tb, their biodistribution, dosimetry, preclinical therapy, and their comparison with conventional PSMA ligands. Our guest is one of the leading scientists in radiochemistry for cancer detection and therapy, the wonderful Jason Lewis. We talk about the importance of using 161Tb - this novel radionuclide for radioligand therapy - and its favorable decay characteristics as compared to 177Lu. We learn about the added value of the emission of Auger electrons which can effectively eliminate micro-metastasis and when combined with ibuprofen-based PSMA ligands offering albumin-binding properties, tumor uptake and therapeutic efficacy are significantly boosted. Besides this fascinating science, don't miss some very important advice from a very successful scientist in a very competitive environment about work-life balance, prioritising expectations and goals - just never forget to "smell the roses"…Selected Publication: Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy. Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller. Journal of Nuclear Medicine Jul 2023, jnumed.123.265524; DOI: 10.2967/jnumed.123.265524https://jnm.snmjournals.org/content/early/2023/07/13/jnumed.123.265524Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

       Relebogile speaks to Dr Ntanganedzeni (N) Muambadzi a Specialist in Nuclear Medicine and  Molecular Imaging.See omnystudio.com/listener for privacy information.

GUEST: Annemie Van Der Linden, AntwerpIn this edition of ‘Dive into Imaging Science' we discuss the brain and the mechanisms that it employs to clear unwanted waste material whilst we sleep with our former ESMI President and Emeritus Professor Annemie Van Der Linden - an outstanding figure and incomparable scientist.We learn how closely coupled this system - known as the glymphatics - is to blood circulation, and how physical stimulation can enhance glymphatic flow in anaesthetised but not awake mice. Along the way, we learn how curiosity and a wondering mind has led Annemie to use a wide range of models to study the brain, from fish to song birds.Selected Publication: Glymphatic influx and clearance are accelerated by neurovascular coupling. Holstein-Rønsbo S, Gan Y, Giannetto MJ, Rasmussen MK, Sigurdsson B, Beinlich FRM, Rose L, Untiet V, Hablitz LM, Kelley DH, Nedergaard M. Nat Neurosci. 2023 Jun;26(6):1042-1053. doi: 10.1038/s41593-023-01327-2. Publication reference: Holstein-Rønsbo S, Gan Y, Giannetto MJ, Rasmussen MK, Sigurdsson B, Beinlich FRM, Rose L, Untiet V, Hablitz LM, Kelley DH, Nedergaard M. Glymphatic influx and clearance are accelerated by neurovascular coupling. Nat Neurosci. 2023 Jun;26(6):1042-1053. doi: 10.1038/s41593-023-01327-2. Epub 2023 Jun 1. PMID: 37264158. https://www.nature.com/articles/s41593-023-01327-2Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

GUEST: Elisabeth de Vries, GroningenIn this episode we talk about nectin-4 - an emerging biomarker for cancer diagnosis and therapy - with one of the most influential and distinguished scientists in medical oncology, Elisabeth de Vries. We talk about the first-in-human study of a radioligand that can target nectin-4 and learn what medical oncologists need to get out from imaging data so that these powerful tools continue to make an impact on patient outcomes. We learn about the importance and best practices for robust clinical trials and the hurdles to both design and finance them. Along the way, we get a glimpse into Elisabeth's career path and how her research combines nuclear with optical imaging modalities as methods to improve patient diagnosis and treatment.Selected Publication: "First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma" published in Clinical Cancer research by the authors X. Duan, L. Xia, Z. Zhang, Y. Ren, M. G. Pomper, S. P. Rowe, X. Li, N. Li, N. Zhang, H. Zhu 6, Z. Yang, X. Sheng, X. Yang  (groups from Beijing University and Johns Hopkins University Baltimore).Publication reference: Xiaojiang Duan, Lei Xia, Zhuochen Zhang, Yanan Ren, Martin G Pomper, Steven P Rowe, Xuesong Li, Nan Li, Ning Zhang, Hua Zhu 6, Zhi Yang, Xinan Sheng, Xing Yang. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023 Apr 24;CCR-23-0609. doi: 10.1158/1078-0432.CCR-23-0609. https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-23-0609/726342/First-in-Human-Study-of-the-Radioligand-68Ga-N188Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

Wissenschaftliche Fragestellung sind komplex – deswegen braucht es spezialisierte Forscherinnen und Forscher. Genauso wichtig ist aber die Kooperation mit Kollegen aus anderen Fachgebieten, denn viele Forschungsfragen können nur im Team bearbeitet werden. Wie das gelingt, berichtet Michael Schäfers, Professor für Nuklearmedizin und translationale Bildgebung sowie Direktor des European Institute for Molecular Imaging der WWU, im Podcast für das Dossier „vernetzt & interdisziplinär“.

Drs Stanley Cohen and Philip Mease review the 2022 ACR meeting topics, including new treatments, trial data, and what they think are the most pressing unmet needs in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984271). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals. Resources Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/ Group for Research and Assessment of Psoriasis and Psoriatic Arthritis https://www.grappanetwork.org/ American College of Rheumatology (ACR) Convergence https://www.rheumatology.org/Annual-Meeting Bimekizumab Treatment in Biologic DMARD-Naïve Patients With Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results From a Phase 3, Randomized, Placebo-Controlled, Active Reference Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive-patients-with-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-phase-3-randomized-placebo-controlled-active-reference-study/ Bimekizumab Treatment in Patients With Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tumor-necrosis-factor-inhibitors-16-week-efficacy-and-safety-from-a-phase-3-randomized-double-blind-pla/ Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients With Active PsA: Pooled 16-Week Results From Phase 3 Randomized, Placebo-Controlled Studies https://acrabstracts.org/abstract/bimekizumab-improvements-in-efficacy-on-disease-activity-assessed-via-composite-endpoints-in-biologic-dmard-naive-and-tnfi-ir-patients-with-active-psa-pooled-16-week-results-from-phase-3-randomized/ Bimekizumab Versus Adalimumab in Plaque Psoriasis https://pubmed.ncbi.nlm.nih.gov/33891379/ A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Naïve Patients With Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial https://pubmed.ncbi.nlm.nih.gov/31563894/ GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/ Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Psoriatic Arthritis: 52-Week Results From a Randomized Phase 2 Trial https://acrabstracts.org/abstract/safety-and-efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-patients-with-psoriatic-arthritis-52-week-results-from-a-randomized-phase-2-trial/ Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis From the Phase 2 PAISLEY Study https://acrabstracts.org/abstract/deucravacitinib-reduces-interferons-b-cell-pathways-and-serological-biomarkers-of-systemic-lupus-disease-activity-pharmacodynamic-analysis-from-the-phase-2-paisley-study/ Nanobody: A Promising Toolkit for Molecular Imaging and Disease Therapy https://pubmed.ncbi.nlm.nih.gov/33464410/

GUEST: Bernd Pichler, TübingenIn this episode we learn how a new lensless microscope, costing just $100 (!), can be used to evaluate radiotracer retention in cells, and discuss potential applications for this revolutionary new technology with our famous guest Bernd Pichler. We discuss how this, and other technologies, could be used to assess the heterogeneous cell populations of the tumour microenvironment and identify cell senescence using new radiotracers developed in Bernd's lab.Selected Publication: "Development of a Lensless Radiomicroscope for Cellular-Resolution Radionuclide Imaging" published in Journal of Nuclear Medicine by the authors Justin S. Klein, Tae Jin Kim and Guillem Pratx (Physical Oncology Lab at Stanford  Medicine).Publication reference: Justin S. Klein, Tae Jin Kim and Guillem Pratx. Development of a Lensless Radiomicroscope for Cellular-Resolution Radionuclide Imaging. J Nucl Med 2023 Mar; 64(3):479-484. doi: 10.2967/jnumed.122.264021. Epub 2022 Sep 15.https://jnm.snmjournals.org/content/64/3/479Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

Dr. Gayatri Gowrishankar, a cancer researcher, talks about how her professional life collided with her personal life when her daughter was diagnosed with a brain tumor. After a number of confusing symptoms, Gayatri followed her motherly instinct when she felt something wasn't right with her daughter's health. Dr. Gowrishankar talks about what her daughter remembers about her experience at the age of 9,  the power of positivity for kids with cancer, and reaching out for support as a caregiver. She also talks about ways to better the experience for childhood cancer patients in India. 1. The power of imaging for cancer early detection 2. How a personal cancer diagnosis motivates and inspires professional work in the cancer research lab 3. Following motherly instinct to push for a diagnosis for your child 4. Caring for yourself when you're a cancer patient's caregiver About the guest: Dr. Gayatri Gowrishankar is a research scientist deeply invested in the business of diagnosing diseases. After being awarded a PhD in Biochemistry from the University of Hannover, Germany, she moved to California to continue her postdoctoral studies in the Molecular Imaging Program at Stanford University where she was introduced to the power of using molecular information to diagnose complex diseases like cancer. She stayed on at Stanford University as a Research Scientist under the mentorship of the late Professor Sanjiv Sam Gambhir who was a pioneer in the field of Molecular Imaging and laid the foundations for early detection programs in Oncology. At Stanford, her work focused around developing novel diagnostic imaging agents, particularly positron emission tomography (PET) tracers for Oncology and Infectious Diseases. She has co-authored numerous scientific publications and participated in several scientific conferences. She is now working in the External Partnerships/Scientific affairs division of Visby Medical, a growing start-up in Silicon Valley with a mission of bringing diagnostics to the patients. Key Moments: 6 minutes: On the science behind and impact of PET scan imaging - Cancer cells are continuing to grow, proliferate and divide, so they need energy and consume a lot of glucose. So that's why they take up this glucose tracer. Then the patients go through the PET scanner and the area where the glucose has been taken up just lights up. And it turns out, it's an exquisitely sensitive modality, or imaging technique, because it's able to pinpoint very small masses of cells all over your body. It tells you where all the cancer has spread in a patient. 22 minutes: On the uncertainty before test results - I think all the mother's listening in will identify because you know when there is something really wrong. You know when there's a simple thing like a scrape and they just need a bandaid. But you know when something's not right with your child. 41 minutes: On reaching out for emotional support as a caregiver -  So I made use of that because I felt like I needed to talk to someone. And it was hard to talk to my husband because we were both so emotional, and we would just break down talking to each other. So I had to reach out for help. Visit the Manta Cares website Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support

Alzheimer, Parkinson and EpilepsyThese are degenerating neurons! Neurodegeneration! Our Biomedical Imaging in Neurodegeneration, Book in progress. Join us! By the way- Are you forgetting? Hybrid Imaging Techs, molecular-MRI and neuromolecular- Neuromolecular Imaging.-NMi.Let's put them together. The new kid on the block is working on the next generation sensor- a manufacturer, philanthropist and investor are needed to come together. A licensee is welcome. Let's talk.on the show- 866 451 1451. All techs can see it all!!!!! Then, why is the new kid's tech needed? Each one does something different. Economy, size, no tracers, no tunnels, small encasement and small scanning device- a big word, potentiostat but the device is handheld it is so small and so on.Straight from the team business plan- the benefits- view here.. .Nanobiosensors with NMI: Advanced Sensing Nanotechnology Over Prior Art · Live imaging· Continuous imaging· Inexpensive imaging· No restraint required· Real-time monitoring· In-vivo, in-situ or in-vitro· Generates specific neurochemical "signatures" or waveforms· Reliable signalling for months· Specific brain locations· Molecular Imaging of targeted neurochemicals · Simultaneous brain signalling as movement is monitored· Cause and effect are closely related· Control and disease signalling leads to personalized medicine· Point of Care Medicine· No bacterial infection· No gliosis, scar tissue formed.· Signals not blocked by scar tissue· Direct imaging independent of flow rate· Superior temporal and spatial resolution· Superior operational stability and steady state control· Same subject comparison data· Superior design· Compatible materials· Compact miniature nanobiosensor· Compact miniature amplifier· Low resistance· High conductance· Faster electron transfer· No interference from white noise· Less equipment· Modern portable equipment· Imaging under anesthesia· Imaging while subject is moving· Imaging while subject is behaving in natural state· Imaging while subject is behaving in diseases of movement· Works with Micro Machines(MEMS) Who is Dr. Broderick? Answer: View CV on the screen. What will she do with the funds? Answer: Hire the people she needs to manufacture and market.What company will do it? Answer- Eazysense and Eazysense can merge! Eazysense holds 200 shares.Where will she and her team do it? Her lab, the manufacturer's lab also because more than one lab is necessary. Roald Dahl: Listen with glistening eyes, the world around you as the secret is hidden in the most unusual places. See the magic, the magical, the miracle of the brain! The discoverable is discovered. Dr. Broderick wishes to pass on the joy of discovery!Meet with the youthful, electrochemist, neuroscientist and pharmacologist, see how Albert Einstein College of Medicine, St..John's University, St. Thomas Aquinas College, Cornell University, Bronx Community College. Cathedral HS, and Msgr. Scanlan HS played a role in her life. See how a life of unassuming dedication molded her brain to discover. A life of solitude in prayer mixed with the joy of family, colleagues, friends.Mental bandwidth-let's connect off the show!CUNY Med School -212 650 5479and broderick@med.cuny.eduThe Broderick Brain FoundationPO Box 596, Bx NY, 10465-1111Good night, Good morning, and Good afternoon, all over the world. ...and that's a wrap.

GUEST: Zaver Bhujwalla, BaltimoreIn this episode we discuss how targeting fibroblasts rather than tumour cells may be an effective strategy for both surgical guided resection and as an anti-cancer therapy with Tim's “academic grandmother”, Zaver Bhujwalla. We discovered Zaver's roots as a physicist and mathematician, learned about her (unpredictable) interest in cancer metabolism and how she combines tools to develop a powerful in vitro diagnostic test.Selected Publication: "Design and characterization of fibroblast activation protein targeted pan-cancer imaging agent for fluorescence-guided surgery of solid tumors" published in Journal of Materials Chemistry B, by the the authors Mukkamala R, Lindeman SD, Kragness KA, Shahriar I, Srinivasarao M, Low PS (Purdue University, West Lafayette, USA).Publication reference: Mukkamala R, Lindeman SD, Kragness KA, Shahriar I, Srinivasarao M, Low PS. Design and characterization of fibroblast activation protein targeted pan-cancer imaging agent for fluorescence-guided surgery of solid tumors. J Mater Chem B. 2022 Mar 23;10(12):2038-2046. doi: 10.1039/d1tb02651h.https://pubs.rsc.org/en/content/articlelanding/2022/TB/D1TB02651HFurther information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

In this edition of Prostate Cancer Uncensored, hear from Mr. Faulk, a prostate cancer survivor, in a discussion with Dr. Joseph Osborne, the Chief of Molecular Imaging and Therapeutics, Professor of Radiology at Weill Cornell Medicine and Attending Radiologist at New York-Presbyterian/Weill Cornell Medicine. To learn more or to listen to additional episodes of Prostate Cancer Uncensored, visit zerocancer.org.

GUEST: Clemens C.W.G. Lowik, RotterdamIn this episode we discuss and learn about Bioluminescence Imaging and modern tools for multiplexed imaging of different colors, tackling a major challenge of the field. Our guest is one of the founding fathers of the ESMI and pioneers on multicolor BLI, the one and only  Clemens Lowik. We talk about innovative approaches for unmixing multiple luciferase-luciferin pairs and quantitative analyses of bioluminescent mixtures, enabling serial tracking of heterogeneous cell populations. On the course of our discussion we learn on how such methods will help advance BLI to cover new exciting regimes, but also spill over to the wider optical imaging. If you're on to exciting developments of the field - listen carefully!Selected Publication: "Multiplexed bioluminescence imaging with a substrate unmixing platform" published in Cell Chemical Biology by the authors C. K. Brennan, Z. Yao, A.A. Ionkina, C.M. Rathbun, B. Sathishkumar, J.A. Prescher (University of California, Irvine, USA).Publication reference: C. K. Brennan, Z. Yao, A.A. Ionkina, C.M. Rathbun, B. Sathishkumar, J.A. Prescher. Multiplexed bioluminescence imaging with a substrate unmixing platform. Cell Chem Biol. 2022 Nov 17;29(11):1649-1660.e4. doi: 10.1016/j.chembiol.2022.10.004. Epub 2022 Oct 24 .https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(22)00358-0Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

GUEST: Simon Cherry, UC DavisIn this episode we discuss (and learn a lot about!) positronium imaging with the co-inventor of Total Body PET, the wonderful Simon Cherry, the physics behind positronium formation, and how it might provide further biological information than standard positron emission tomography imaging. We learnt about Simon's journey that led him to change the field of clinical PET imaging and what new innovations he has up his sleeve... and if you are looking for a research area that is just waiting to be explored - listen carefully! Selected Publication: "Positronium imaging with the novel multiphoton PET scanner" published in Science Advances by the the authors P Moskal, K Dulski, N Chug, C Curceanu, E Czerwiński, M Dadgar, +30, and W. Wislicki (Kraków, Poland).Publication reference: P Moskal, K Dulski, N Chug, C Curceanu, E Czerwiński, M Dadgar, +30, and W. Wislicki. Positronium imaging with the novel multiphoton PET scanner. Sci Adv 2021 Oct 15;7(42):eabh4394. doi: 10.1126/sciadv.abh4394. Epub 2021 Oct 13.https://www.science.org/doi/full/10.1126/sciadv.abh4394Further information on the European Society for Molecular Imaging: https://e-smi.eu/Contact: office@e-smi.eu

GUEST: Jolanda de Vries, NijmegenIn this episode the hosts Tim and Giannis talk with the fantastic Jolanda De Vries from Nijmegen about how dendritic cell therapy got her into imaging and the latest therapeutic cell imaging methods. We touch on multimodality imaging, why imaging isn't frequently used in the clinic for cell tracking, and why mouse models of cancer might never be good enough.Selected Publication: "In vivo imaging of nanoparticle-labeled CAR T cells" published in Proceedings of the National Academy of Sciences (PNAS) by the authors L. Kiru, A. Zlitni, A. Michael +9, and H. E. Daldrup-Link (Pediatric Molecular Imaging Lab at Stanford Medicine).Publication reference: Kiru L, Zlitni A, Tousley AM, Dalton GN, Wu W, Lafortune F, Liu A, Cunanan KM, Nejadnik H, Sulchek T, Moseley ME, Majzner RG, Daldrup-Link HE. In vivo imaging of nanoparticle-labeled CAR T cells. Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2102363119 https://www.pnas.org/doi/full/10.1073/pnas.2102363119Further information on the European Society for Molecular Imaging: https://e-smi.eu/Contact: office@e-smi.eu

This episode features Simon Cherry, PhD, discussing his recent 2022 Annual Meeting Cassen Award Lecture and more in a wide-ranging conversation with SNMMI President, Munir Ghesani, MD.In his lecture—A Matter of Time—at the SNMMI 2022 Annual Meeting, Cassen Award Winner Simon Cherry, PhD , explored time, and its role in nuclear medicine, from historical developments occurring over decades, to technologies that can detect photons with a precision of tens of picoseconds. Inspired by the groundbreaking ideas of Benedict Cassen and others, Dr. Cherry charted the journey from the past and into the future to create the ultimate imaging devices for studying the body and its many interacting systemsThe Benedict Cassen Prize is awarded by the Education and Research Foundation (ERF) for Nuclear Medicine and Molecular Imaging in recognition of outstanding achievement and work leading to a major advance in nuclear medicine science.

Heather Jacene, MD, SNMMI Scientific Program Chair, sits for a conversation with E.G. Elisabeth de Vries, MD, PhD—the SNMMI 2022 Annual Meeting Henry N. Wagner, Jr., MD, Lectureship Speaker—for a preview of her lecture: Seeing the Light with Molecular Imaging for Systemic Cancer Treatment Decisions. 

Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities CME Available: https://auau.auanet.org/node/36003 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up. 2. Determine the benefits of combined functional and anatomical information gained through accurate matching of anatomical (CT/MRI) and functional (PET) images. 3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests. 4. Utilize performance characteristics of standard and emerging molecular imaging modalities to stage urologic oncology patients. 5. Describe the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.

Timestamps: 3:05 - Running a coffee shop from a dorm room 9:50 - Why biology is the most advanced tech on Earth 13:32 - How to program proteins 15:05 - Vegan, sustainable collagen 23:30 - Surviving climate change About Mitchell Duffy: Mitchell Duffy is the CEO and co-founder at Cambrium, a next-generation materials company utilizing the molecular programmability of proteins to re-imagine the products you use everyday. Originally hailing from the US, he majored in Biology and Computer Science at Tufts University, did his masters in Synthetic Biology in London and his PhD in Molecular Imaging in Germany. Shortly after finishing his PhD he became an Entrepreneur in Residence at Merantix, the ML incubator created by Adam Locher. It was here that he developed his idea for Cambrium, which he founded in 2020. Cambrium's crede is that biology is the most advanced tech on Earth: from robots, to swarm intelligence, to carbon removal, nature has already perfected what we are still struggling to achieve. The problem that Cambrium tackles is that materials make up 23% of greenhouse gas emissions, the vast majority of them having been gouged from the Earth, pumped from the ground or sliced from the bodies of animals. Man-made materials have, in fact, already surpassed all the biomass on Earth. Cambrium wishes to go from an extractive to a generative way of producing materials, and they plan to do so through the programming of proteins. How do you program proteins? Well, proteins are made of 20 amino acids — you put these amino acids in different orders and you get completely different properties, different materials. Ever since the protein folding problem was solved in 2020, people have been able to program and test protein designs in their labs. Cambrium has done this with collagen, and created a completely vegan and sustainable version of it for cosmetic products. Memorable Quotes: "Materials represent 23% of greenhouse gas emissions. In 2020, the weight of man-made materials came to outweigh every biomass on Earth." Don't forget to give us a follow on our Twitter, Instagram, Facebook and Linkedin accounts, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly give-aways or founders dinners!

This podcast is all about MMST (Master in Medical Science and technology) Programme of IIT, Kharagpur, India. Post MBBS a lot of graduates are interested in exploring technology driven medical career, this course is somewhat in that direction. Dr.Hara prasad speaks to one of his friends DrLokesh about this course and tries to dissect the whole course. Dr Lokesh Rajagopal(aka Dr.Loki) from Tamil Nadu finished his MBBS in 2015. Post that he has couple of years of clinical experience as a resident doctor before joining MMST programme at IIT-KHARAGPUR. In case you want to connect with him, reachout via linkedin. LINKEDIN ID of Dr.LOKI - https://www.linkedin.com/in/drlokeshrajagopal. The MMST program offered by the School is the only comprehensive physician-scientist training program in India which aims to bridge the gap that has historically separated biological sciences from engineering and physical sciences. The major benefit of this course is that it creates well equipped and highly skilled medical professionals who are capable of handling advanced technology in the field of medical sciences. It provides training for state-of-the-art medical research in frontier areas of Medical Imaging, Molecular Imaging and Image Analysis, Biomaterials and Implants, Biophysics, Medical Statistics, Telemedicine, Biomedical Instrumentation, Early Detection of Cancer, Immuno-technology, and the like. The MMST program is unique in the way that its the only comprehensive physician-scientist training program in India which aims to bridge the gap between biological sciences, engineering and physical sciences. An assistantship of Rs.25, 000/ per month is given to all the eligible students. The admission to MMST Programme is offered to students each year on the basis of an entrance examination conducted all over the country. As the School of Medical Sciences and Technology IIT Kharagpur has collaboration with top hospitals and research centers all over the country, it is an added advantage for the students associated with the institute. Some of the areas identified for teaching and R&D activities of the School are: Medical Imaging & Image Analysis Telemedicine & Tele Surgery Reproductive Health Healthcare Information Management System Preventive & Promotive Health Care System Bio-markers and their application in Oncology Tissue Engineering BioMaterials Bio - MEMS in Medicine Bio -MEMS & Sensors Wound Healing Research Herbal Medicine Instrumentation, Rehabilitation Engineering

Benjamin Pulli, MD, is a fellowship trained interventional neuroradiologist with a focus on vascular disorders of the brain, head/neck, and spine. He employs state-of-the-art minimally invasive endovascular and percutaneous surgical techniques to treat patients with intracranial aneurysms, acute stroke, brain arteriovenous malformations, dural arteriovenous fistulas, tumors, and chronic back pain. Having grown up in Austria, Dr. Pulli moved to the US after completing medical school in Innsbruck, Austria. He completed post-doctoral research training in Neuroradiology and Molecular Imaging at Harvard Medical School, followed by a Radiology residency and Neuroradiology fellowship training at the Massachusetts General Hospital in Boston. He then completed a second fellowship in Interventional Neuroradiology/Endovascular Neurosurgery at Stanford University. Dr. Pulli has authored more than 40 peer-reviewed publications and received prestigious scientific grants from institutions such as the Radiological Society of North America and Ernst Schering Foundation. To learn more about Dr. Pulli and other PNI Doctors please visit https://www.pacificneuroscienceinstitute.org/about-us/our-team/

On this episode, PrecisCa speaks with David M. Schuster MD, FACR. Dr. Schuster is a Professor in the Department of Radiology and Imaging Sciences at Emory University School of Medicine. Dr. Schuster also serves as Director of the Division of Nuclear Medicine and Molecular Imaging, and is a Georgia Research Alliance Distinguished Scientist. Board certified in radiology and nuclear medicine, he specializes in molecular medicine and integrative imaging. Dr. Schuster sits down with us to explain PET Scans, false readings & the importance of selecting the right scanners for the right situation. Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

The key to being customer centric is understanding your customers. And the best way for you, as a marketer, to understand your customer is to leave the friendly confines of your office or Zoom call and actually engage with the people you're trying to market to. Sonia Sahney of GE Healthcare joins me for a discussion about customer insight, and ways to help your customers better understand their customers. Sonia is the CMO of Molecular Imaging at GE Healthcare. You can find her on LinkedIn.

Photo: Logo of CASIA, part of the unified Chinese effort to control the world Internet.* 1/4: Welcome to the Chinese Academy of Science Institute of Automation, CASIA, the heart of the heart of PRC supremacy online (and Philip K. Dick's imagination).   Glenn Tiffert  @HooverInst;  Jeff Stoff, @HooverInst https://www.hoover.org/events/eyes-wide-open-ethical-risks-research-collaboration-china Glenn Tiffert is a research Fellow at the Hoover Institution and a historian of modern China. He manages the Hoover project on China's Global Sharp Power Project Jeffrey Stoff, Senior Analyst, Department of Defense .. * CASIA Research Departments Key Laboratory of Molecular Imaging, Chinese Academy of Sciences State Key Laboratory of Management and Control for Complex Systems Precise Perception and Control Research Center Digital Content Technology and Media Service Research Center Center for Research on Intelligent Perception and Computing Brainnetome Center National Laboratory of Pattern Recognition The Sino-French Laboratory in Computer Science, Automation and Appl... Research Center for Brain-inspired Intelligence Intelligent Manufacturing Technology and System Research Center National Engineering & Technology Research Center for ASIC Design

The Oncology Journal Club - Delivering Oncology News DifferentlyThe Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 58 in our series The Oncology Journal Club.Welcome to this week's episode of The OJC. Join Eva Segelov, Craig Underhill and Hans Prenen as they chat through the latest papers.In today's episode Hans Prenen lives up to the challenge of not covering colorectal cancer! Instead he looks at improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Craig talks us through treatment of older adults with cancer and guidelines to improve trial participation.  You'll also find out why Eva Segelov has been a little naughty this week.We've quick bites, ‘The Paper That Changed My practice' segment and the amazing paper of the week. And listen out for next week's episode – it's our OJC Christmas Special featuring the best bloopers of the year plus a surprise guest.Full bios and the list of all papers discussed are available on our website.For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

Commentary by Dr. Valentin Fuster

In this week's episode, we talk to Dr. Jeff Thompson, Ph.D., NYPD detective and the creator of the Warr;or21 Project. This week's focus is on self-care and so much more.  We talk about the stresses that PIOs are faced with and how to manage themselves. Jeff explains how to normalize fear, stress, and anxiety. Jeff cover "reframing", which helps take control and gives perspective and the importance of it. Jeff explains what Warr;or21 Project is the Awe Project and the purpose of positivity for success. This episode is packed with great resources for anyone in a high-stress career. A bit about JeffJeff Thompson, Ph.D., is an Adjunct Associate Research Scientist at the Molecular Imaging and Neuropathology Research Area of the New York State Psychiatric Institute and also the Center for the Prevention and Treatment of Depression in the Psychiatry Department at Columbia University Medical Center.  His research includes developing resilience and positive mental health strategies, hostage negotiation in terrorist incidents, suicide prevention, psychological autopsies, and the use of effective communication during crisis incidents. His training material has been implemented in police agencies across the United States and beyond. Additionally, he is an 18-year law enforcement veteran detective with the New York City Police Department (NYPD) and a former hostage negotiator. In his role at the NYPD, Detective Thompson is currently the Mental Health and Wellness Coordinator helping conduct research and outreach on the department's suicide prevention and postvention efforts, reducing the stigma associated with mental illness and help-seeking, enhancing resilience through evidence-based practices, and raising awareness of resources available to both police officers and the public. Dr. Thompson is the recipient of the Griffith University Arts, Education and Law's 2020 Outstanding International Alumnus Award and The New York City Police Foundation's 2020 Hemmerdinger Award for Excellence for Distinguished Public Service.  Learn about Warr;or21 and the Awe Project by going to Resiliencesymposium.orgJeff's Twitter handle @jeffphd       Support the show (https://t.co/GOmAg9X6e8?amp=1)

This month on Episode 27 of Discover CircRes, host Cynthia St. Hilaire highlights four original research articles featured in the July 23rd and August 6th issues of Circulation Research. This episode also features an in-depth conversation with Drs Ana Gomez and John Pierre Benitah, from INSERM and the Paris-Saclay University, about their study, Impaired Binding to Junctophilin 2 and Nanostructural Alterations in CPVT Mutation.   Article highlights:   Glasenap, et al. Imaging Inflammation and Fibrosis in Heart Failure   Shi, et al. Cardiomyocyte Pyroptosis Aggravates MI/R Injury   Koenis, et al. SPM Temper Phagocyte Responses in COVID-19   Zhang, et al. Common Origin of Heart and Extraembryonic Lineages   Cynthia St. Hilaire:     Hi, and welcome to Discover CircRes, the podcast to the American Heart Association's journal, Circulation Research. I'm your host, Dr Cynthia St. Hilaire from the Vascular Medicine Institute at the University of Pittsburgh, and today I'll be highlighting articles presented in our July 23rd and August 6th issues of Circulation Research. I also will speak with Drs Ana Gomez and John Pierre Benitah, from Inserm and the Paris-Saclay University, about their study, Impaired Binding to Junctophilin 2 and Nano-structural Alterations in CPVT Mutation. Cynthia St. Hilaire:     The first article I want to share comes from the July 23rd issue of Circ Res, and it's titled Molecular Imaging and Inflammation and Fibrosis in Pressure Overload Heart Failure. The first author is Aylina Glasenapp and the corresponding author is James Thackeray, and they're from Hanover Medical School in Germany. After a heart attack, inflammation and fibrosis of the heart alter cardiac contraction and can lead to its failure. Currently, for ischemic heart failure, doctors use imaging techniques such as positron emission tomography, and cardiac magnetic resonance imaging, to measure the inflammation and fibrosis to provide a prognosis. Cynthia St. Hilaire:     However, whether these imaging techniques are useful for non-ischemic heart failure was unknown. To find out, this group performed transverse aortic constriction on mice, which is a commonly used method to model non-ischemic heart failure, and then they analyzed the animal's hearts with positron emission tomography to assess the inflammation and cardiac magnetic resonance imaging to quantify scar tissue. Compared with Sham-operated animals, those that underwent TAC exhibited increased heart inflammation for at least three weeks and significant fibrosis for at least six weeks. The degree of scarring and inflammation was inversely correlated with heart function. The team also found that reversal of TAC led to reduced inflammation and fibrosis over time. Together, the results confirm that these imaging modalities are valuable for monitoring fibrosis and inflammation in non-ischemic heart failure, and they could potentially be useful for assessing the effectiveness of interventions. Cynthia St. Hilaire:     The second article I want to share is titled GSDMD Mediated Cardiomyocyte Pyroptosis Promotes Myocardial Ischemia Reperfusion Injury. The first author is Huairui Shi and the corresponding author is Junbo Ge, and they're from Fudan University in China. After myocardial infarction, restoring blood flow is essential to saving muscle function. However, restoration of flow itself causes damage by inducing inflammation and cell death. This study found that the cell death aspect of a reperfusion injury occurs via a process called pyroptosis, which is a controlled form of necrosis that is due to excessive inflammation. Cynthia St. Hilaire:     The team developed an in vitro model of reperfusion injury, where cultured cardiomyocytes are starved and then resupplied with oxygen. Using this model, they found that cells exhibited features of pyroptosis, including the release of inflammatory factors, increased production of the pyroptotic factor gasdermin D and cell death. Cardiomyocytes lacking gasdermin D did not display signs of pyroptosis under these same conditions. The team went on to show that gasdermin D was significantly increased in the hearts of mice following ischemia reperfusion. And compared with control animals, mice whose cardiomyocytes were engineered to lack gasdermin D, suffered less necrosis and smaller reperfusion injuries in their hearts. Together, these findings provide insights into the mechanisms that should be targeted to minimize pyroptosis and subsequent ischemia reperfusion injury, following myocardial infarctions. Cynthia St. Hilaire:     The next article I want to share is titled Disruptive Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19. The first authors are Duco Steven Koenis, Issa Beegun and Charlotte Camille Jouvene, and the corresponding author is Jesmond Dalli. And they're from Queen Mary University of London. Inflammation is essential in the early stages of battling and invading pathogen, but at the same time, inflammation can become damaging to the host if it is not resolved in a timely manner. Prolonged and unresolved inflammation is responsible for the hospitalizations and deaths of many COVID-19 patients. An excess of circulating pro-inflammatory cytokines is one of the key features of severe COVID-19. And now, Koenis and colleagues show that certain pro-resolving factors are out of balance in these severe patients. Cynthia St. Hilaire:     Blood samples from patients with mild COVID-19 showed an increase in specialized pro-resolving lipid mediators. However, blood from patients with severe COVID-19 had lower levels of these pro-resolving lipid factors. Expression of specialized pro-resolving lipid mediator receptors on phagocytes was also higher in patients with mild disease than those with severe COVID-19. And, in line with this, the proportion of activated pro-inflammatory phagocytes was higher in patients with severe disease. Cynthia St. Hilaire:     When patients were treated with the steroid dexamethasone, they subsequently inhibited the increased levels of the specialized pro-resolving lipid mediators in the blood. Together, these results reveal specialized pro-resolving lipid mediators are dysregulated in severe cases of COVID-19, and the findings suggest increasing these pro-resolving lipid mediators could promote resolution of out-of-control inflammation. Cynthia St. Hilaire:     The last article I want to share is titled Unveiling Complexity and Multi Potentiality of Early Heart Fields. The first authors are Qinqguan Zhang and Daniel Carlin, and the corresponding authors are Sylvia Evans, Joshua Bloomekatz, and Neil Chi, and they're from UC, San Diego. The developing heart is thought to originate from two populations of cells; the first and the second heart fields. And these are first identifiable at stages E 7.5 in the mouse, or on day 15 in the human embryo. Genes controlling the development of these fields have been linked to congenital heart defects, but interestingly, congenital heart defects are also sometimes linked to placental abnormalities. However, the mechanisms underlying this link have been unclear. Now this study has gone on to discover an unexpected link between the first heart field and extra embryonic tissues, which give rise to the yolk sack and the placenta. Cynthia St. Hilaire:     Through lineage tracing experiments and single cell transcriptomics, the team discovered that the first heart field consists of two sources of mesoderm progenitor cells, one source that is embryonic in nature and the other source arises from the interface between the extra embryonic and the embryonic tissue of the early gastrula. This latter population of progenitor cells, which is defined by the expression of the transcription factor hand one, gives rise to extra embryonic mesoderm cells in addition to the two Hartfield cell populations. The discovery of this shared source of mesodermal progenitors not only blurs the lines between the embryo and its supporting tissue but may also explain the link between placental abnormalities and congenital heart defects. Cynthia St. Hilaire:     Today I have with me Drs Ana Gomez and Jean-Pierre Benitah, and they're from Inserm and the Paris-Saclay University. And today we'll discuss their study Impaired Binding of Junctophilin 2 and Nano-structural Alterations in CPVT Mutation. And this article is in our July 23rd issue of Circulation Research. So thank you both very much for joining me today. Jean-Pierre Benitah:    Thank you. Ana Gomez:                Thank you. Cynthia St. Hilaire:     You're in Paris, so we're trying to match it so we're all meeting our normal workday on a Friday. So I very much appreciate you taking the time to meet with me. So this study is investigating a rare disease called Catecholaminergic Polymorphic Centricular Tachycardia, or CPVT. So can you describe to us what is CPVT and how does this disease present in patients? Ana Gomez:                Okay, so CPVT stands for Catecholaminergic Polymorphic Centricular Tachycardia. So it is a genetic disease that appears mainly in childhood and youth with sudden death. So the patients don't have any remarkable problem, either in the electrocardiogram or arteries, or in the cardiac structure by echocardiography, and they seem healthy. But when they have stress, it can be emotional or it can be physical, so during exercise, it presents with syncope or sudden cardiac arrest. So the problem is that, many of the times, the first symptom is the death of a child playing soccer or doing exercise and then the only treatment that they, so far, it's beta blockers, to avoid this stress, and also flecainide and propafenol. But these treatments are still not completely efficacious, or sometimes the people need to get implant defibrillator. It's a big cost and it's also stressful because if the patient feels that they have to recharge, that supposes stress, and this stress is bad for them. Cynthia St. Hilaire:     Right, so it's like if they feel a flutter, it makes them more stressful, which can exacerbate. That is terrifying. And so the goal, I guess, regarding gaps in knowledge that are leading to your investigation, what was known about this disease before you started your study? And where did you leap off from that? Jean-Pierre Benitah:    Up to now, what we know about the disease is an alteration of the calcium homeostasis in cardiac myocyte. That could induce trivial activity, and then arrhythmia and cardiac sudden death. So mainly the mutation related to an intracellular calcium channel called Ryanodine receptor. So it's up to 60% of the patient with this mutation, but also you have a mutation related also to proteins that are in-buried in the control of the Ryanodine receptor activity, priadine, calmodulin. Cynthia St. Hilaire:     Yeah, that was actually going to be my next question. So I know this cardiac Ryanodine receptor 2, or RYR2, it's obviously the channel component that helps to release that calcium signal, but it's part of a larger complex. I believe it's called the Calcium Release Unit. Can you talk about what is in that unit in terms of proteins and then where those other genetic mutations fit into that? Ana Gomez:                Yeah, so the Calcium Release Unit is formed by a cluster of Ryanodine receptors. So in the reticular cardiomyocytes, these are mostly in the junction of sarcoplasmic reticulum that is very close to the sarcoplasmic reticulum membrane inside the cardiomyocyte, inside the cell. So the channel is internal. But it's very close to the sarcolemma in the T-tubule invaginations where the L-type calcium channels are located. So this is... The channels are very important to activate contraction, so it's heartbeat. The calcium entry through the attached calcium channel on the surface makes some calcium get into these very restricted spaces, like 20 nanometers, and in this space this calcium activates the Ryanodine receptor. So the Ryanodine receptor is activated by calcium and these release much more calcium than is needed for the contraction. So the problem of the CPVT is that the channels may release calcium during diastole, so when calcium should be low because they had to relax. Ana Gomez:                For your new question, which proteins? So the main proteins are the Ryanodine receptor. But Ryanodine receptors are a very big macro complex. They are the biggest channels that are known and they have a big cytoplasmic portion with proteins that can bind to them, and most of them just keep the channel quiet. So this may be calmodulin, FKPB 12.6, or 12, sorcin. And then there are also some other proteins that scaffold kinases, like PKA and CaM kinase. And also they have some proteins that moderate the channel from the luminal side. So, calsequestrin, triadin and junctin. And this agents to fill in that we will speak later. It's important because it binds to the L-type calcium channel and to the ryanodine receptor. So it's important to keep the dyad structure. It's not only a structural role. Cynthia St. Hilaire:     Yeah, that is so interesting. So your study focused on a very specific mutation. It's the RYR2 arginine in the 420 spot to glutamine mutation. So I guess my first question is based on the patient population, how common is this specific mutation? How common is that? Ana Gomez:                Yeah. So in fact, I'm going to say that it's very common, because normally CPVT is one mutation, one family. Cynthia St. Hilaire:     I see. Ana Gomez:                Even if they are located in hotspots, but these particular mutations, we were approached by a cardiologist working in Spain who had this family with a child that died at the age 14, playing soccer game. And so Dr Zorio in Valencia, she found this RyR2 420Q mutation. And at this time this was the first mutation in this site. I mean, not really in the site, there was already RyR2 420W that was already, so it was the same spot, but different. Cynthia St. Hilaire:     That was my next follow up question to that. My PhD was biochemistry, so this brought back having to memorize the amino acid structure. So arginine is large and positively charged to glutamine is neutral. So what were the experiments that you designed to help determine the functional causes of this mutation? You know, in addition to just, okay, obviously there's a charge change, so there's probably a structural or a binding change, but how did you determine the functional consequences of this mutation? Ana Gomez:                The structure, as you say, this has been shown. In fact, they was the first family, but then also in this region, there was another family and in Israel also there is another family. So there are three, but the structural limitations that these arginine is neutral. It has been shown by a laboratory, who works in Vancouver, in a structural and the end terminal has like three logs and these are 420. It's important to hold a chloride that in the middle and, and to hold the position. So, but this is not the functional, the functional is what we were going to analyze. So the first thing that we did is to analyze calcium sparks because calcium sparks is the functional, let's say elementary event, of calcium release to RyR2 receptors. So we start analyzing calcium sparks in the cells and we found strange things, like very long calcium sparks that was not so clear in other CPVT models, even one that we studied earlier. And so then we started to continue to know why we have longer calcium sparks and different kind of analysis. So we also collaborate with some other laboratories to do the ultrastructure of the dyad by electromicroscopy. Ana Gomez:                And then we found that the sarcoplasmic reticulum, junctional sarcoplasmic reticulum, was enlarged. So we thought, well, maybe the channel, the calcium spark is longer because locally they delayed depletion. So we did another kind of experiment changing the volume of the SR and it was not so concluded so we found that it may contribute to longer calcium sparks, but it doesn't explain for it. So then we start with to analyze different proteins candidates, also the phosphorylation of course. And then we didn't find in most of these proteins, like FKVP. Cynthia St. Hilaire:     Kind of a standard go-tos. None of them were involved. Yeah. Ana Gomez:                Yeah. And then, because there is this ultrastructural alteration, we thought of junctophilin and that is how we found that junctophilin binding was impaired. Cynthia St. Hilaire:     That's a perfect segue. You're hitting all of my next questions. So can you tell us a little bit about, what did you find regarding junctophilin and the RyR2 channel? Jean-Pierre Benitah:    So mainly, junctophilin act to us the good structural design between the ryanodine receptor and the trigger L-type calcium channel. And people say that junctophilin binds to both proteins to keep them close to each other. So mainly what we found is that we don't have activation of the expression of junctophilin, but it seems that with this mutation the junctophilin is less in contact with ryanodine receptor. But it's not the case for the L-type calcium channel. It seems that coimmunoprecipitation experiments that we've done show that junctophilin stayed still with the L-type calcium channel, but have a lower affinity to the ryanodine receptor when you have this mutation. What was really important is that we saw that not only in the mouse model where we induce this mutation, but also in cardiomyocytes derived from induced pluripotent stem cells from patients that have this mutation. Cynthia St. Hilaire:     I think that's one of the great strengths of your study. You know, I like how you took a multi-faceted approach, you know, using these IPS cells from the patients and also created a knock in model. Previous studies had used more global or whole exon deletions. So how is your knock-in able to identify additional information that built upon those former studies? Ana Gomez:                Maybe this is not an exact answer to your question, but what I think is that the strength of our study or one of the strengths of our study is that we have the patients with electrocardiograms working, we have the cells from the patients. So we have...Our IPS cell is from one of the persons that have been patient, and the control line is from his brother. So we have the two brothers. They are still living, and we have the mice and everything is in the same point mutation. So in this thing, because there is a lot of, let's say, critics to the IPS cells studies because they are not mature and they don't look like an adult cardiomyocyte. And I think that besides CPVT, we can also show that of course cardiomyocytes derive from IPS cells. They are not adult, but they are still a good model because we recapitulate the same thing. Ana Gomez:                So we can mix the human context to really have what happened in patients, because that is the important thing, but we also need to manipulate the in vivo animals and there are some things that we cannot do. We cannot get adult cardiomyocytes from patients, so for that, we have the mice and we can also analyze from in vivo to the molecular level. So I think that it's a big strong point from our study that you take compared to others, that they are only in mice or only in IPS, cannot do this correlation. Then, each mutation, we think that it may, or at least each region of the mutation, may have different mechanisms. So if we find these longer calcium sparks in these R420Q mutation, it doesn't mean that because we also have other studies in C-terminal mutation, and we don't find longer calcium sparks, we just find more. So this is not because of the design of the study, but because the mechanism of the mutation is different. Cynthia St. Hilaire:     In terms of translational potential, what do your findings suggest about either the ability to screen patients potentially for the development of CPVT or actually more importantly, you know, therapies to help treat these patients when they're identified? Jean-Pierre Benitah:    Yeah. It's one of the big problems with the CPVT, especially since when you look at the different mutations, those are different mutations that have been reported on the ryanodine receptor located on different hotspots on the ryanodine receptor. And it's seems that each hotspot could have a different type of mechanism behind that. So, for example, we show, there you see, you know, different mutations in collaboration with CPVT or 420Q mutation. So the mechanism was related to an alliteration of the sensitivity of the ryanodine receptor to the calcium. So the group of branching show that in other mutations, in other spots, hot spots, it was related in fact, to a modification of this. Also the sensitivity of calcium of the ryanodine receptor calcium, but from the luminal side. Ana Gomez:                Regarding your first question was diagnosis. I think that after our work, we may also include junctophilin, because so far there has not been any link to junctophilin for sensitivity. So when a patient has CPVT, they start screening for mutations in the ryanodine receptor, since it was found that this child was involved and then in other proteins. So I think now if they don't find in a patient, because there are still like 40% of CPVT patients that the mutation has not been found. Ana Gomez:                For therapeutic side maybe find a molecule that stimulates the binding of junctophilin to ryanodine receptor, but also maybe some smaller molecule that may interact between the N-terminal and the core solenoid because we found that in the interim molecular structure, they show tighter association between the N-terminal and the core solenoid. So maybe it's more of a tide or something that can be in between too. I mean, I don't know, but it's first line there. Cynthia St. Hilaire:     Potential, but still far off. That's wonderful. So are some of these mechanisms, I assume, they would also be relevant in non-genetic forms of tachycardia? Is that the case? Could some of your findings also perhaps be applied to the tachycardia related to heart failure or other types of disease states? Ana Gomez:                I think it's actually, for example, junctophilin binding to ryanodine receptor in heart failure. It has not been yet studied, but we want to do it. It's something because as you say heart failure, it's a very common disease. So it's also very relevant to the public health. This is something that we need to know. Jean-Pierre Benitah:    One of the things that happens in heart failure is that it seems also that you are a dissociation between the calcium channels and the ryanodine receptor because you have less tissue formation. So perhaps this is difficult to try to figure out whether it would be the same, but perhaps this activation between the communication between the two channels is one of the main points that we have in CPVT and in heart failure related to tachycardia. Ana Gomez:                Yeah. In fact, many years ago we showed that. We showed that in heart failure there is a defect in calcium channel and ryanodine receptor. So in this study it was only functional. We didn't do the structure, but of course it is something that we have to keep in mind, continue investigating. Cynthia St. Hilaire:     Yeah. Well that sounds like a great future project. Well, I want to thank you so much for joining me today and helping to discuss your paper. I love it when we take rare diseases and figure out the mechanism with hopefully applying it to more common disease states. That's what I do in my lab with vascular calcification, and so thank you so much for joining me and for this great publication. And we look forward to your future work that is hopefully in Circ Res. Jean-Pierre Benitah:    Thank you for the invitation. Ana Gomez:                Yeah, thank you very much for your time. Cynthia St. Hilaire:     That's it for the highlights from the July 23rd and August 6th issues of Circulation Research. Thank you for listening. Cynthia St. Hilaire:     Please check out the Circ Res Facebook page and follow us on Twitter and Instagram with the handle @CircRes and #DiscoverCircRes. Thank you to our guests, doctors Ana Gomez and John-Pierre Benitah. Cynthia St. Hilaire:     This podcast is produced by Ashara Ratnayaka, edited by Melissa Stoner, and supported by the editorial team of Circulation Research. Some of the copy text for the highlighted articles was provided by Ruth Williams. I'm your host, Dr Cynthia St. Hilaire, and this is Discover CircRes, your on-the-go source for the most exciting discoveries in basic cardiovascular research. This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more information, visit ahajournals.org.  

Podcast Contents 0:00-1:15–Introduction by Jeffrey S. Klein, MD, Editor of RadioGraphics. 1:16-05:10–Nonepithelial Tumors of the Larynx: Single-Institution 13-Year Review with Radiologic-Pathologic Correlation. Ong et al, RadioGraphics 2020; 40:2011–2028.   05:11-09:29–One Algorithm May Not Fit All: How Selection Bias Affects Machine Learning Performance. Yu and Eng, RadioGraphics 2020; 40:1932–1937.  09:30-14:03– Abdominal Imaging Manifestations of Recreational Drug Use. Mansour et al, RadioGraphics 2020; 40:1895–1915.  14:31-18:21–Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics. García-Figueiras et al, RadioGraphics 2020; 40:1987–2010. 18:22- 22:29–Chest CT in COVID-19: What the Radiologist Needs to Know. Kwee and Kwee, RadioGraphics 2020; 40:1848–1865.  22:30-24:23–Pulmonary COVID-19: Multimodality Imaging Examples. Ko et al, RadioGraphics 2020; 40:1893–1894. 24:24-24:52 Outro RSNA2020 Virtual Meeting https://www.rsna.org/annual-meeting

Commentary by Dr. Valentin Fuster

In this podcast, we speak to Dr Patrick Veit-Haibach, author of a recent BJR Review on Nuclear medicine and molecular imaging advances in the 21st century.

Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary, and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: I'm Greg Hundley, Associate Editor, Director of the Poly Heart Center at VCU Health in Richmond, Virginia. Dr Carolyn Lam: Today's feature discussion is the first huge look at the global, regional and national burden of calcific aortic valve disease and degenerative mitral valve disease over a huge period, from 1990 to 2017. Very important discussion coming right up after this coffee chat. Greg, do you mind if I go first? Dr Greg Hundley: Go ahead, Carolyn. Dr Carolyn Lam: The first paper I want to talk about applies novel single cell transcriptomics to unveil new insights into pressure overload cardiac hypertrophy. Here's your quiz, Greg, ready? Dr Greg Hundley: Well, I'm choking on my coffee here, but go ahead. Dr Carolyn Lam: All right, I was thinking of asking you about single cell transcriptomics but let me just tell you the results. Single cell RNA sequencing is a new and rapidly advancing technique that can comprehensively characterize gene expression and relationships among individual cells. Dr Wang from Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, and Peking Union Medical College and colleagues analyze the transcriptomes of 11,492 single cells and identified major cell types, including both cardiomyocytes and non-cardiomyocytes based on their molecular signatures. They did this at different stages during the progression of pressure overload induced cardiac hypertrophy in a mouse model. Their findings not only illustrated dynamically changing cell type crosstalk doing pathological cardiac hypertrophy, but also shed light on strategies for cell type and stage specific interventions in cardiac disease. For example, subtype switching of macrophages was found to be a key event underlying the transition from normal to decline dejection fraction in cardiac hypertrophy. Thus, targeting macrophages in hypertrophy for example, during the switch could attenuate disease progression. All of this is discussed in an editorial by doctors, Zhang and Zhou from University of Alabama in Birmingham. Dr Greg Hundley: Oh wow. Carolyn very important macrophage infiltration and another role for those, that cell type. Well, my first paper gets at the topic of reversal of these factor Xa inhibitors. In this particular patient population, it's the situation where we're dealing with intracranial hemorrhage. The article comes from Dr G Morgan Jones and colleagues from the University of Tennessee Health Sciences Center. Since the approval of oral factor Xa inhibitors, there have been few papers published really regarding the ability to neutralize the anti-coagulate effects of these agents, particularly after intercranial hemorrhage. Dr Carolyn, this is a multi-center, retrospective, observational cohort study of 433 patients. Then it received apixaban, or rivaroxaban, and then developed an intercranial hemorrhage. They then subsequently received prothrombin complex concentrates in that period of time between 2015 and 2019. Dr Carolyn Lam: Wow. How did these participants who had intracranial hemorrhage, how did they fare after receiving these prothrombin concentrates? Dr Greg Hundley: Yeah, well, administration of the prothrombin complex concentrates after, apixaban or rivaroxaban in the setting of intracranial hemorrhage, provided a high rate of excellent or good hemostasis. That was in nearly 82%, coupled with an adverse consequence of 3.8% of those experiencing a thrombosis. Thrombosis occurred in 25 patients who had a total of 26 thrombotic events of which 22 occurred in the first 14 days, following the prothrombin complex concentrate administration. One patient had documentation of an infusion related reaction. For the full cohort of patients, in the hospital mortality was 19% and the median ICU care and hospital length of stay were two and six days respectively. Carolyn, these cohort analyses seemed to demonstrate the possibility of success and similar to other observational cohort studies. The results of this study suggest that future randomized control trials evaluating the clinical efficacy of these prothrombin complex concentrates in patients with factor Xa inhibitor related intercranial hemorrhage are needed. Dr Carolyn Lam: Nice, Greg. You know what? I'm going to start with a quiz. True or false, heart failure with reduced ejection fraction is characterized by blunting of the positive relationship between heart rate and left ventricular contractility known as the force frequency relationship? Dr Greg Hundley: Well, Carolyn, this is one of those where if I go 50/50, you'll knock out the wrong answer. Let's say, I'm going to go, true. Dr Carolyn Lam: You're so right, Greg. This next paper really deals with this. It's from corresponding author, Dr Witt from Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds in UK and colleagues who previously described that, tailoring the rate responsive programming of cardiac implantable electronic devices in patients with HFrEF based upon individuals noninvasive force frequency relationship data, really improves exercise capacity. Addressing this reduce force frequency relationship and HFrEF.  Now in the current paper, they sought to examine whether using force frequency relationship data to tailor heart rate response in HFrEF with inpatients, with HFrEF and cardiac implantable electronic devices would favorably influence exercise capacity and left ventricular function six months later. They conducted a single center, double blind, randomized parallel group trial in 83 patients with HFrEF. With a cardiac implantable electronic device and randomized to tailored rate response programming based on these individuals force frequency relationship versus conventional age guided rate response programming. The primary outcome measure was changed in walk time on a treadmill walk test. Dr Greg Hundley: Wow, Carolyn. So this is a really detailed analysis. What did they find? Dr Carolyn Lam: They found that rate adaptive cardiac implantable electronic device programming taking into account the at normal force frequency relationship in these patients, was associated with improved exercise time. Force frequency relationship guided heart rate settings had no adverse effects on left ventricular structure and function. While conventional settings were associated with a reduction in left ventricular ejection fraction. Out of the box age guided rate adaptive pacing, might be a sub optimal choice in patients with heart failure and an assessment of the force frequency relationship might be of clinical benefit in facilitating personalized rate adaptive programming. Dr Greg Hundley: Very nice. Dr Carolyn Lam: Thanks Greg, but there's other stuff I want to tell you about in this issue. There's a research letter by Dr Gambier on Molecular Imaging of Infective Endocarditis with Floral Multiple Trials PET-CT. This is the first time that a Florine 18 PET tracer has been used to specifically image bacterial infection of the heart valves with high sensitivity and specificity in an animal model. Dr Greg Hundley: Oh, good job, Carolyn. Those flooring tracers, very interesting. Another application perhaps. Well, in a perspective piece, I have an article Carolyn from Dr Orly Vardeny from University of Minnesota Medical School in Minneapolis and remembers the prior cardiovascular complications from influenza. And how those experiences may be useful in anticipating some of the cardiovascular complications that we may see from SARS-CoV-2. In a separate article, Dr Aatish Garg and collaborators from VCU Health, present an ECG case of syncope in an individual with severe aortic stenosis status post bioprosthetic aortic valve replacement and coronary artery bypass grassing. Who also has paroxysmal AV block? Then finally, Carolyn, Professor Concepcion Peiró from Universidad Autónoma in Madrid. Has an on my mind pace discusses ACE inhibition and our abuse in relation to the SARS-CoV-2 to virus bonding to ACE two binding sites within the respiratory epithelium. Well, Carolyn, how about we get on to that feature discussion? I can't wait to hear about aortic and mitral valve disease over nearly 30 years. Dr Carolyn Lam: Let's go Greg. Nondramatic valvular heart disease is really common throughout the world. However, no studies have previously estimated their global or national burden, that is until today's feature paper. That's part of the Global Burden of Disease, or GBD, 2017 study. I am so pleased to have with us a corresponding author, Dr Greg Roth from University of Washington. As well as Victoria Delgado, our associate editor from Leighton University Medical Center. What a great topic to discuss. Nondramatic valvular heart disease, meaning calcific aortic valve disease, degenerative module valve disease, all the stuff we see and have to deal with now. Greg, could you please tell us about this GBD effort and really what you found? Dr Greg Roth: Let me tell you a little bit about the Global Burden of Disease Study and then why we wanted to explore this question and then what we found. I am the lead for cardiovascular research at the Institute for Health Metrics and Evaluation in Seattle at the University of Washington. We're the coordinating center for the Global Burden of Disease Study. It's now in its second decade, and it's a large-scale effort to quantify the lost health due to early death and disability for every country in the world. This is a huge effort with over 5,000 people around the world working on it. We work closely with governments around the world, as well as the World Health Organization, as well as county, state, and other authorities in the US. Our goal is really to bring together all of the evidence in the world to bear on important health policy questions. One of the areas that I've had a long interest in is valve disease. I'm a practicing cardiologist at our county hospital here in Seattle, as well as an echocardiographer. I was really excited by the idea of bringing together my passion for taking care of patients with valve disease and looking at how to use diagnostic imaging to take better care of them and the disease modeling research that I do at the institute. We decided a couple of years ago after exploring the global patterns of rheumatic heart disease, that we would turn our focus towards these really important questions of non-rheumatic valve disease. There's obviously a very large literature and lots of active research around the clinical pathways that we need to follow for patients with calcific valve disease and mitral valve disease that's not due to rheumatic causes. Obviously in recent years, we've got amazing technologies and interventions that we're using more and more frequently like percutaneous interventions. However, we had not done the work to turn this really interesting tool, the Global Burden of Disease Study, towards looking at these important causes. We pulled together every data source we could find on the population level burden of nonrheumatic valve disease and then using a range of techniques, and we rely heavily on tools that come out of data science. These include computer disease modeling tools that we've developed as well as ensemble models and other sort of big data approaches to pull all of this together into comparable, consistent estimates of death and prevalence. Then we're also really interested in using those to estimate what we call summary metrics of health, like disability adjusted life years. We do this for a very long time series. So we went back all the way to 1990 and we looked all the way to 2017. Then we're able to get a really good sense of not only what the impact of these diseases are, but how they compare to the 350 other diseases that we estimated in exactly the same way for the Global Burden of Disease Study. Also, where is the burden of these particular conditions going up? Where is it going down? We're really excited to be able to pull that together into this paper. In which we report the global, regional, and national burdens of calcific aortic valve disease and degenerative mitral valve disease. As well as a right sided valve disease that's not due to congenital endocarditis causes, which we estimate separately in the study. Dr Carolyn Lam: Greg, you say, you're excited. I can definitely speak, I think on behalf of both Victoria and Augie, that we're the ones excited publishing this really great piece of work here in circulation. You know personally, I'm a great fan of your work in GBD. Tell us the results. Dr Greg Roth:  What we found was that in 2017, there was an estimated 12.6 million cases of calcific aortic valve disease in the world and 18.1 million cases of degenerative valve disease globally. With higher rates of calcific valve disease, among men and higher rates of degenerative valve disease among women. Now that is an aggregate. We've produced estimates for every country in the world and for larger countries with more than 200 million people, we've gone down to what we call the first administrative level. So, US states, Chinese provinces, and we do this in the larger countries, but when you add it all up, you get those numbers. We also found that there were just over a hundred thousand deaths globally each year due to calcific aortic valve disease and about 35,000 deaths reported due to degenerative mitral valve disease. I think this is really interesting because of course, as clinicians, we have a lot of experience with sources like cohort studies, and trials, and registries, but we have not actually looked at what's actually the world's largest public health reporting system, which is vital registration, meaning death certificates. Now, most of us have filled out that certificates and we always wonder, how reliable are there? And there's clearly limitations. In fact, a huge amount of our work at the Global Burden of Disease Study is dealing with the limitations of death certificates, looking for bias, and adjusting that bias when we can, but these are death certificates where somebody's entered these causes as the underlying cause of death. I think when that actually shows up on a death certificate, that's actually a real signal to us that there was a physician out there who felt pretty strongly that that was the sort of trigger that led to the patient's death. We also found that aging and population growth are leading to about a hundred percent increase over this period of time over the last 25 years in the number of deaths due to these nonrheumatic valve diseases. If we age standardized, we see that the trend is flat, but if you're running a health system or a minister of health, you need to hear that message that with aging and population growth affecting almost every country in the world, you're going to see dramatic rises in the number of cases of both of these conditions showing up on the doorstep of all of your hospitals. Dr Carolyn Lam: Fantastic Victoria, could you put these findings in context for us and maybe take us behind the scenes a little bit at what the editors thought? Dr Victoria Delgado: These are very important data, because so far, for example, we have, as Greg said, registries and one of the most known registries was for example, in Europe, The Valvular Heart Survey that was done in 2001, if I remember well. Has been redone recently, it was last year published in circulation. The other one with a very large data is coming from counties. With similar data to the results that are publishing now. For example, if you compare those two registries with much smaller populations, in US, they always report much, much frequently the genetic mitral valve regurgitation. While in Europe, aortic stenosis is the most frequent one, calcific aortic stenosis. Here, I was again surprised with in the global population that again, degenerative mitral valve regurgitation is much more prevalent than calcific aortic stenosis, but you can see that there was an increase of 124% in the prevalence of calcific aortic valve disease in 2017. I wonder if this is related to the awareness of the risk associated with aortic stenosis and they invent of a new therapies, transcatheter therapies, with the TAVI for example, or transcatheter aortic valve replacement, which has opened the door for an effective treatment for many patients that before were simply denied for surgery. I don't know if you have further insights into that. Dr Greg Roth: Yes. I think that's a really important point, that we see a lot of variation in the data. While we have millions of death certificates to look at all around the world. Really scores of millions, where we can look for trends and patterns. The population level data on nonrheumatic valve disease is actually quite limited compared to most diseases. We did a very aggressive perspective review of the published and gray literature and found about 50 sources reporting prevalence for these conditions that were usable in our study. For the most part, those studies are not long time series. We have to estimate trends, piecing together data from different populations. Now, there are a couple of places in the world where you can get a long trend of time where they've gone back repeatedly in the same population and looked with echo, which you obviously need here to make these diagnoses. As far as we can tell, and these are just a handful of studies, the trend is flat. We don't see large increases. Now, the increases in our study were completely driven by aging and population growth and the age standardized rates. The epidemiologic pattern for this disease is that it's flat and for mitral valve disease, maybe trending down a little bit. I think it's clear that in places where there's been a lot of attention paid either because of new therapies, like TAVR or new access to diagnostic screening with the growth of echo cardiography and other screening methods, that is a limitation of the study, for sure. I think what it really focuses me on is the idea that we need better data. We need to think about ways and probably more cost effective ways of surveilling for these conditions, but I'll tell you something that was really interesting, that we found is that, in the United States where we relied heavily on administratively coded data, because we have that in a uniform format for every state and we have a long time series for that, and we have complete vital registration. We looked at the state level and we found that the all ages rate, was actually going up. Meaning it wasn't just population growth and aging, but in about a third of the states, the true epidemiologic rate of the disease was going up. Meaning it's becoming more common even if you control for the change in age structure of a country like the United States over time. I think that given the fact that we're seeing this explosion of obesity around the world, and we know that atherosclerotic risk factors can be a major driver of let's say calcific aortic valve disease. I mean, an interesting question is, is valve disease going to be sort of a canary in the coal mine? Are we going to see more of it at younger ages? Traditionally it's been the oldest patients who actually survived the longest and tend to be healthier, who we can actually find having the disease, but I wonder, are we going to see more of that as patients present with more obesity. Unfortunately we know that reversing or controlling those atherosclerotic risk factors hasn't paid off in big ways for preventing calcific aortic valve disease. It's complex and like mitral valve disease, clearly there's likely to be a very strong genetic component as well. Dr Carolyn Lam: Greg, you mentioned a little bit more about the age effect, but you did mention some sex differences. Could you just clarify a little bit about that and maybe the interaction between the two? Dr Greg Roth: What we've all been taught, or at least what I was always taught, was that there was more mitral valve disease in women. We actually did find that in the study and that was reassuring because when we went back to look for the source of that sort of common teaching, actually, it's pretty hard to find. I think it actually comes, my guess is, from a lot of people's clinical practice. To see that match-up between what we thought was going to be true in terms of the relative prevalence by sex for these two major diseases, calcific aortic valve disease and degenerative mitral valve disease was reassuring. It suggested that the data we have is actually picking up on real patterns and patterns that match sort of our clinical experience as well. One of the interesting things about the interaction between age and sex, is that women live much longer on average than men. As women age into those oldest years, what we actually see is a decline in the burden of disease. There's an increase in stroke, but for everything else, those women are truly survivors. Actually we see less bowel disease and cardiovascular disease in general, in the oldest old women. What we do see is a massive rise in cognitive impairment and dementia. That's a very active area of research for us right now. The interaction between atherosclerotic risks, which can drive things like valve disease and of course, coronary disease and stroke and then the cognitive impact is a really important area of research. There are a couple of great papers that have come out even just in the last few weeks. I think this question of how risk is going to impact people in those oldest age groups? Is really important. We know the population is aging. We know that in some places, life expectancy is increasing to the point where we really need to rethink what the disease patterns are going to be in the oldest old. Dr Carolyn Lam: Indeed. So the feminization of aging is kind of what I like to call it, but yikes Victoria. Could I maybe ask you to please give the final words of advice and maybe the take home messages? Dr Victoria Delgado: I think that this data are really welcomed because as Greg said, we need to understand better how we can modify the prognosis of these prevalent and how we can tackle it and for that we need data. I think that these are very welcomed data. Now, how we are going to do it in the future? That's a great question. I don't have the answer right now, but I think that increasing the awareness that nonrheumatic valvular heart disease can impact as well on the outcomes of the population, is important to know. I think that people need to have access to diagnostics best particularly echo cardiography is very available imaging technique and very feasible. We can have right now developments where we can do the echo cardiography with our phone by adding one of the probes. I think that in the future, we may see more and more valvular heart disease that probably was already there, but we just need to increase the awareness. From those data, learn how we can treat those individuals if they need and how we can improve the outcome of these individuals. Dr Carolyn Lam: Thank you, Victoria. Thank you, Greg. More awareness and more good data needed. Thank you, audience, for joining us today. You've been listening to Circulation on the Run. Don't forget to tune in again next week. Dr Greg Hundley: This program is copyright the American Heart Association, 2020.  

Neste novo episódio do Gene Highlights, a Dra. Daniela Cardinal de Vasconcellos faz uma revisão sobre a demência - aspectos clínicos e a importância da avaliação anatômica e molecular integrada. Confira a agenda de reuniões do Gene em https://spr.org.br/evento/25/grupo-de-estudos-de-neurorradiologia-gene/programacao e participe online (https://spr.org.br/cursos-via-web/). Segue abaixo o link do artigo dessa entrevista: Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging - https://pubs.rsna.org/doi/10.1148/rg.2020190070

In this podcast we discuss the exciting rapidly growing field of molecular imaging in lung disease, with a focus on it’s role in pulmonary fibrosis. We interview Dr. Sydney Montesi and Dr. Peter Caravan on their research in this field, including their work on imaging albumin extravasation in the fibrotic lung and imaging freshly deposited collagen as a marker of disease activity.

Jeffrey S. Klein, MD, Editor of RadioGraphics, discusses six articles from the January-February 2020 issue of RadioGraphics. ARTICLES DISCUSSED: Role of Multimodality Imaging in Gastroesophageal Reflux Disease and Its Complications, with Clinical and Pathologic Correlation. RadioGraphics 2020;40:44-70. Phase-Contrast MRI: Physics, Techniques, and Clinical Applications. RadioGraphics 2020;40:122-140. Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging. RadioGraphics 2020;40:200-222. Learning from Gamers: Integrating Alternative Input Devices and AutoHotkey Scripts to Simplify Repetitive Tasks and Improve Workflow. RadioGraphics 2020;40:141-150. Avulsion Injuries of the Hand and Wrist. RadioGraphics 2020;40:163-180. Pearls and Pitfalls for Soft-Tissue and Bone Biopsies: A Cross-Institutional Review. RadioGraphics 2020;40:266-283.

Science and medicine are at an exciting crossroads. Recent developments in the clinical laboratory are being implemented in research hospitals and will soon be used to diagnose diseases across the U.S. In this talk, Amanda Hummon will illustrate some of the recent breakthroughs in molecular imaging technologies and how they are being used to help cancer patients.

IFE Distinguished Visitor Lecture - recorded 30 May 2019 at QUT. Associate Professor New's research involves developing molecular imaging tools to understand the interactions of metals with cellular functions, with a focus on fluorescent and magnetic resonance sensors. In this lecture, she presents progress made in studying three main aspects of cellular inorganic chemistry: imaging the metabolites of metal-containing drugs; tools to study cellular metal pools; and studies of redox homeostasis of cells varies with drug treatment. The lecture will specifically cover strategies to optimise the properties of molecular imaging sensors.

IFE Distinguished Visitor Lecture - recorded 30 May 2019 at QUT.Associate Professor New's research involves developing molecular imaging tools to understand the interactions of metals with cellular functions, with a focus on fluorescent and magnetic resonance sensors. In this lecture, she presents progress made in studying three main aspects of cellular inorganic chemistry: imaging the metabolites of metal-containing drugs; tools to study cellular metal pools; and studies of redox homeostasis of cells varies with drug treatment. The lecture will specifically cover strategies to optimise the properties of molecular imaging sensors.

Norris Cotton Cancer Center Grand Rounds presented on October 9, 2018 Sunil Singhal, MD Director of Thoracic Surgery, Penn Medicine

Episode 3 is generously sponsored by start.ca. On this episode: The Transformation of Care Dr. Irene Hramiak, Site Chief of Medicine and the Centre for Diabetes, Endocrinology and Metabolism at St. Joseph’s Health Care London and a Professor and Division Chair at Western's Schulich School of Medecine and Dentistry talks about about how a rebuilding a century-old hospital from the ground up has led to new discoveries and treatments in patient care. Watch some videos about the transformation here. Scanning The Mysteries Dr. Lisa Saksida (twitter), Canada Research Chair in Translational Cognitive Neuroscience Dr. Ravi Menon (twitter), Canada Research Chair in Functional and Molecular Imaging, Medical Director at CFMM (twitter) Dr. Adrian Owen (twitter), Canada Research Excellence Chair in Cognitive Neuroscience at Western University All three exceptional scientists tell us about sixty-six million dollar study that involves, scientists, doctors, musicians, artists, and business people looking into the most mysterious organ we have through BrainsCAN (twitter). Meet Our Future Robot Surgeons Dr. Christopher Schlachta at CSTAR, London Health Sciences Centre is blending virtual reality with real-world robots to make surgery safer, faster, and more accessible. Watch a video about Nick Paparella's experience with robotic surgery.

Today's interview is with Dr. Cristal Glangchai. Dr. Cristal Glangchai has worked in intellectual property, technology commercialization, and product development. She received her B.A. in Plan II, B.S. in Mechanical Engineering, and M.S. and Ph.D. in Biomedical Engineering from The University of Texas at Austin, where she was recently a featured alumni. In addition, she holds two doctoral certificates in Nanoscience and Nanotechnology, and Molecular Imaging for Diagnostic and Therapeutics. She is a scientist, entrepreneur, and mentor with a passion for teaching and engaging kids, especially girls, in technology and entrepreneurship. She is the Founder/CEO of VentureLab, a non-profit that runs experiential learning programs in youth tech entrepreneurship. She is also the Director the Blackstone LaunchPad at UT and the Director of The Texas Entrepreneurship Exchange at the University of Texas at Austin. In 2015 she was a selected speaker at TEDx San Antonio, where she inspired others with her personal story, “From Stand-up to Start-up: Growing Girl Techies and Entrepreneurs.” Dr. Glangchai also spoke at TEDxYouth and was also named “Woman of the Year” by the San Antonio Business Journal (and she was named one of the 40 Under 40 in the journal’s annual awards). In 2016, she was a featured speaker at SXSWInteractive and SXSWEdu, and she was named Non-Profit CEO of the Year by the San Antonio Business Journal. In the Spring of 2017 she was featured for the grand-opening of the Blackstone LaunchPad at UT. Dr. Glangchai’s work has been featured in the Wall Street Journal, the TODAY Show, NPR’s The TakeAway, Mashable, Medium, Silicon Hills News, Rivard Report, San Antonio Express-News, and San Antonio Business Journal.  Resources Mentioned In The Episode TEDx Talk: https://www.youtube.com/watch?v=yi5tpOtpKsw TEDx Youth Talk: https://vimeo.com/145735835 Venture Lab: http://venturelab.org/ See acast.com/privacy for privacy and opt-out information.

Today on Entrepreneur Effect Dush is Joined by Cristal Glangchai, PhD. Over the years, Dr. Glangchai has worked in intellectual property, technology commercialization, and product development. She received her B.A. in Plan II, B.S. in Mechanical Engineering, and M.S. and Ph.D. in Biomedical Engineering from The University of Texas at Austin, where she was recently a featured alumni. In addition, she holds two doctoral certificates in Nanoscience and Nanotechnology, and Molecular Imaging for Diagnostic and Therapeutics. Dr. Glangchai is a member of Springboard Enterprises, a nonprofit resource hub of entrepreneurs and investors dedicated to building high growth, technology-oriented companies led by women. She is also a mentor for the TechStars Austin chapter. In addition, Dr. Glangchai is affiliated with the American Society for Engineering Education, American Society of Mechanical Engineers, Controlled Release Society, BioAustin, Austin Women in Technology, RICE Alliance, RampCorp, Geekdom, and Geekdom Fund.

Applied Molecular Imaging of Dopaminergic Circuitry in the Islets of Langerhans f/ Paul Emerson Harris, Ph.D.

Dr. Albert J. Sinusas: Multi-Modality and Molecular Imaging of Cardiac Remodeling

Thu, 8 May 2014 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17855/ https://edoc.ub.uni-muenchen.de/17855/1/Knoop_Kerstin.pdf Knoop, Kerstin

Thu, 19 Dec 2013 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17318/ https://edoc.ub.uni-muenchen.de/17318/1/Li_Zhoulei.pdf Li, Zhoulei ddc

Molecular imaging-and especially Positron Emission Tomography (PET)-is of increasing importance for the diagnosis of various diseases and thus is experiencing increasing dissemination. Consequently, there is a growing demand for appropriate PET tracers which allow for a specific accumulation in the target structure as well as its visualization and exhibit decay characteristics matching their in vivo pharmacokinetics. To meet this demand, the development of new targeting vectors as well as the use of uncommon radionuclides becomes increasingly important. Uncommon nuclides in this regard enable the utilization of various selectively accumulating bioactive molecules such as peptides, antibodies, their fragments, other proteins and artificial structures for PET imaging in personalized medicine. Among these radionuclides, 89Zr (t1/2 = 3.27 days and mean Eβ+ = 0.389 MeV) has attracted increasing attention within the last years due to its favorably long half-life, which enables imaging at late time-points, being especially favorable in case of slowly-accumulating targeting vectors. This review outlines the recent developments in the field of 89Zr-labeled bioactive molecules, their potential and application in PET imaging and beyond, as well as remaining challenges.

Prof Hedvig Hricak talks to ecancer about molecular imaging at the European Forum on Oncology in Berlin, May 2012. The development of molecular imaging is essential for advancing precision medicine.Tissue biomarkers provide essential information about cancer genetics and other details of tumor biology; however, they depend on limited samples. As has been recently documented, tremendous biological heterogeneity exists within primary lesions, and tumor metastases dedifferentiate. Molecular imaging allows in vivo, non-invasive assessment of biomarkers throughout the entire primary tumour and all metastatic sites. Therefore, it is especially important for developing and implementing predictive biomarkers for determining whether a particular therapy is likely to work in an individual patient or for monitoring treatment response, and it can reveal differences in treatment response among different disease sites. In the laboratory and the clinic, molecular imaging is providing key insights into intra- and intertumoral biological heterogeneity. Prof Hricak discusses the role of molecular imaging in precision medicine, providing some specific examples of techniques now in use and touching on emerging concepts such as integrated diagnostics and theranostics.

Walter J Curran, Jr. Executive Director, Winship Cancer Institute Professor and Chairman, Department of Radiation Oncology, Emory University School of Medicine Group Chairman, Radiation Therapy Oncology Group Atlanta, GA

Walter J. Curran, Jr.   Executive Director, Winship Cancer Institute Professor and Chairman, Department of Radiation Oncology, Emory University School of Medicine Group Chairman, Radiation Therapy Oncology Group

Biennial Cancer Conference. Vortrag von Prof. Adrian A. Lammertsma

Zahi Fayad, PhD, discusses the possibility of using imaging to monitor the effect of angiostatic and anti-inflammatory therapy after administering local drug delivery. (September 5, 2008)

10/18/2006 | Dr. Michael Montalto, Molecular Imaging and Diagnostics Advanced Technology Program, GE Global Research, discusses how GE is using molecular imaging technologies for early detection of diseases. OTHER EPISODES: http://www.ge.com/rss/patentpending.xml. WEB SITE: http://www.ge.com/en/company/news/rss/ (to subscribe to a series, listen or download specific podcasts, and get more information).